Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$4.96−0.04 (-0.80%)
Close on Nov 17, 2026Market cap $193.13MP/E –Yield –
Entrada Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Entrada Therapeutics's price to sales ratio was 45.2× on Nov 11, 2026, against 6.4× a year earlier. Over the last 3 years it ranged from 1.3× to 58.6×, with a median of 3.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 45.2× | +38.8 |
| 2025 | Dec 31, 2025 | 6.4× | +3.4 |
| 2024 | Dec 31, 2024 | 3.0× | – |
See a number that looks wrong?